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ABSTRACT 
Aims: The aim of the present study was to explore the reason why women with diabetes 
lose the female protection against MI, by investigating cardiovascular risk factors, markers 
of inflammation, early predictors for future development of diabetes and clinical 
manifestations in diabetes and coronary heart disease. 
Subjects and methods: Women with (n=29), and without diabetes (DM) (n=64), 
hospitalised with a smyocardial infarction ( MI) 1994-96, were compared with DM-women 
without MI (n=46) and healthy controls (n=125). They were invited to a screening 
examination with questionnaires, physical examination and blood sampling (Paper I). 
Furthermore, titers of antibodies to malondialdehyde-treated LDL (oxLDL), and CRP 
levels, as a measure of the immune response and inflammation, were assessed. (Paper II). 
In addition, 1351 women, aged 39-65 years, without prior DM or CVD, took part in a 
screening investigation in 1979-81 with questionnaires, physical examination and blood 
sampling. Development of DM up to 1998 was identified at a second screening 1997-98 
(Paper III). Finally, we investigated the influence of DM on clinical presentation, in-
hospital course, and short-term prognosis in 6488 men (21.2 % DM) and 2809 women 
(28.7% DM) < 80 years old who were prospectively enrolled in the Euro Heart Survey of 
Acute Coronary Syndromes (ACS) (Paper IV). 
Results: Women with prior MI had, compared with DM women without MI, significantly 
higher waist/hip ratio, and very high s-triglycerides (TG) and low HDL-cholesterol levels. 
They also had higher p-fibrinogen, were smokers and lived a sedentary life to a higher 
degree than the other women. The women with DM and/or MI had higher IgG and lower 
IgM titers of antibodies against oxLDL and higher CRP levels than the healthy controls. S-
TG, overweight, high blood pressure (BP) and low physical activity significantly increased 
the risk of future diabetes. Even slightly elevated s-TG resulted in a considerably enhanced 
risk of DM, which was independent of the other factors. Women with DM and ACS were 
more likely to present with ST-elevation ACS, to develop Q-wave MI, and had higher 
mortality than non-DM women, whereas the differences were smaller in men. The 
interaction between sex and DM was significant. 
Conclusions: Women with DM who have manifested a MI carry a very substantial CVD 
risk factor burden. A pronounced inflammation and differentiated immune response against 
modified LDL might result in a more aggressive atherosclerotic process in women with 
DM and/or MI. Even slightly elevated TG levels and moderately increased BP and 
overweigt have a strong influence on DM risk, independent of other factors. Women with 
ACS are more likely to with ST-elevation ACS, develop Q-wave MI, and have worse 
prognosis than non-DM women, whereas the differences in men are less pronounced. The 
results underscore the importance of implementing evidence based primary and secondary 
preventive measures. They also suggest a differential effect of diabetes on the 
pathophysiology of ACS based on the patient's sex and emphasize the importance of 
analyzing men and women with DM separately. 
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oxidized LDL, triglycerides, WHR, BMI, HDL-cholesterol, ACS 
ISBN 91-628-6243-X Göteborg 2004 
Department of Medicine, Sahlgrenska University Hospital/Östra, 
The Cardiovascular Institute, Göteborg University, 
Göteborg, Sweden. 
Women, diabetes and coronary heart disease 
Annika Dotevall 
Göteborg 2004 
Women, diabetes and coronary heart disease 
ISBN 91-628-6243-X 
© 2004 Annika Dotevall 
annika.dotevall@vgregion.se 
Department of Medicine, S U/Östra, The Cardiovascular Institute, Göteborg 
University, Göteborg, Sweden 
Printed in Sweden 2004 
Vasastadens Bokbinderi AB Göteborg 
Women, diabetes and coronary heart disease 
Annika Dotevall 
Department of Medicine, Sahlgrenska University Hospital/Östra, The Cardiovascular 
Institute, Göteborg University, Göteborg, Sweden. 
ABSTRACT 
Aims: The aim of the present study was to explore the reason why women with diabetes 
lose the female protection against MI, by investigating cardiovascular risk factors, 
markers of inflammation, early predictors for future development of diabetes and 
clinical manifestations in diabetes and coronary heart disease. 
Subjects and methods: Women with (n=29), and without diabetes (DM) (n=64), 
hospitalised with a myocardial infarction (MI) 1994-96, were compared with DM-
women without MI (n=46) and healthy controls (n=125). They were invited to a 
screening examination with questionnaires, physical examination and blood sampling 
(Paper I). Furthermore, titers of antibodies to malondialdehyde-treated LDL (oxLDL), 
and CRP levels, as a measure of the immune response and inflammation, were assessed. 
(Paper II). In addition, 1351 women, aged 39-65 years, without prior DM or CVD, took 
part in a screening investigation in 1979-81 with questionnaires, physical examination 
and blood sampling. Development of DM up to 1998 was identified at a second 
screening 1997-98 (Paper III). Finally, we investigated the influence of DM on clinical 
presentation, in-hospital course, and short-term prognosis in 6488 men (21.2 % DM) 
and 2809 women (28.7% DM) < 80 years old who were prospectively enrolled in the 
Euro Heart Survey of Acute Coronary Syndromes (ACS) (Paper IV). 
Results: Women with prior MI had, compared with DM women without MI, 
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cholesterol levels. They also had higher p-fibrinogen, were smokers and lived a 
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activity significantly increased the risk of future diabetes. Even slightly elevated s-TG 
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to develop Q-wave MI, and had higher mortality than non-DM women, whereas the 
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INTRODUCTION 
Diabetes mellitus 
Diabetes mellitus (DM) is a metabolic disease characterized by 
hyperglycemia resulting from a defect insulin secretion, impaired insulin 
action or both. Cardiovascular disease (CVD) is the greatest single cause of 
morbidity and mortality associated with DM (Joron 1986, Panzram 1987, 
Haffner 1998, Turner 1998, Laing 2003). 
Diabetes is classified into two major types with different pathophysiology. 
Type 1 diabetes is usually caused by autoimmune destruction of the 
insulin-producing beta cells of the pancreas in genetically susceptible 
persons. The process eventually results in absolute insulin deficiency and 
need for exogenous insulin for survival. Type 2 diabetes is a multifactorial 
disease resulting from a combination of insulin resistance and relative 
insulin deficiency. It is frequently a part of the metabolic syndrome, which 
also includes central obesity, hypertension, and hyperlipidemia (Table 1) 
(Alberti 1998). The typical clinical manifestations of diabetes are similar in 
both types, with pronounced thirst, excessive drinking, large urine volumes 
and fatigue. However, it is not unusual for type 2 DM to develop slowly, 
with few symptoms, so that a patient may have been diabetic several years 
before the diagnosis is established. 
Table 1. The metabolic syndrome defined by the US National 
Cholesterol Education Program Expert Panel 2001. 
In clinical practice, the diagnosis of the metabolic syndrome is made 
when three or more of the following features are present: 
Waist circumference >102 cm in men 
>88 cm in women 
s-triglycerides >1.7 mmol/l 
HDL-cholesterol <1.0 mmol/l in men 
<1.3 mmol/l in women 
Blood pressure >130/80 mmHg 
Plasma glucose >6.1 mmol/l 
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Although type 1 DM is most common in children, adolescents, and younger 
adults, there is no upper age limit. Type 2 DM is usually diagnosed in 
adults, but may appear also in younger subjects. In addition, genetic defects 
in insulin production may result in a syndrome similar to type 2 DM that 
occurs in young people. Definition and classification of diabetes have been 
extensively described in reports from the World Health Organization, 
WHO (Alberti 1998) and American Diabetes Association ADA (Report of 
the Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus 1997). 
The prevalence of diabetes worldwide was estimated to be 2.8-4.2 % in 
2000, with an expected increase to 4.4-5.4 % in 2030 (King 1998, Wild 
2004). However, prevalence figures vary widely between different parts of 
the world, ranging between 1 and 18% (King 1998, Wild 2004). In the 
Nordic countries the estimated prevalence of diabetes is reported to be 2-6 
% (Andersson 1991, Tuomilehtol991, Larsson 1995, Vilbergsson 1997, 
Lidfeldt 2001, Eliasson 2002). Whereas type 1 diabetes only constitutes 5 
to 10%, type 2 diabetes comprises the great majority of the diabetic 
population. With increasing rates of obesity and concomitant type 2 
diabetes, the total number of diabetic subjects worldwide is estimated to be 
more than 350 million in the year 2030 (Wild 2004). 
Acute coronary syndromes 
Coronary thrombi develop on ruptured atherosclerotic plaques built up by a 
lipid-rich core with a thin fibrous cap. However, not all plaques are lipid-
rich, and thrombi may also develop on non-ruptured plaques (Naghavi 
2003). Acute manifestations of coronary heart disease, or acute coronary 
syndromes (ACS), comprise a range of clinical conditions, from milder 
forms, such as unstable angina, to myocardial infarction (MI) without ST-
elevation and MI with ST-segment elevation. Pathophysiologically, 
patients with ST-elevation who progress to Q-wave MI are characterized 
by occlusive thrombi in the vast majority of cases (deWood 1983), whereas 
total occlusion is infrequently observed in the early hours of non-Q-wave 
MI (deWood 1986). Among patients with acute MI, those who present with 
ST elevation develop larger infarctions, have more in-hospital 
complications, and have higher short-term mortality than patients without 
ST elevation (Yusuf 1984). 
In studies of patients with acute MI or sudden coronary death, the lipid rich 
plaques prone to rupture were more common in men, whereas women more 
often seemed to develop thrombi on superficial erosions on plaques rich in 
smooth muscle cells and proteoglycans (Farb 1996, Arbustini 1999). In 
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women plaque ruptures seemed to be associated with age (Burke 2001) and 
serum cholesterol (Burke 1998), whereas eroded plaques with thrombi 
were associated with smoking (Burke 1998). In a Norwegian population 
study of 6000 men and women, the prevalence of large, lipid-rich plaques 
was higher in men than in women (Joakimsen 1999). Moreover, the 
presence of diabetes increased the likelihood of developing lipid rich 
atherosclerotic lesions (Moreno 2000). 
Furthermore, angiographic studies revealed a more severe and diffuse 
coronary atherosclerosis in patients with diabetes, especially in women, 
that was not explained by established CVD risk factors (Natali 2000, 
Pajunen 2000). This suggests that plaque morphology might differ in 
women compared with men, and in diabetic compared with non-diabetic 
subjects, and that different pathophysiologal processes may be involved in 
ACS (Arbustini 1999). 
In contrast to men, women with ACS are older (Kudenchuk 1996, 
Hochman 1997, Maynard 1997, Hochman 1999, Hanratty 2000), have 
more hypertension (Kudenchuk 1996, Hochman 1997, Maynard 1997, 
Hochman 1999, Chua 2000, Hanratty 2000) and congestive heart failure 
(Kudenchuk 1996, Maynard 1997, Hochman 1999), but are less often 
smokers than men (Hochman 1999, Hochman 1997, Chua 2000, Hanratty 
2000). Previous studies have shown that the electrocardiographic changes 
characteristic of MI are less pronounced in women than in men (Hochman 
1999, Lundberg 2002). Furthermore, women less often present with ST 
elevation (Lundberg 1997, Hochman 1999, Vaccarino 1999), but more 
often with unstable angina (UAP) compared to men (Hochman 1999). 
Prognosis after an MI has been described to be worse in women than in 
men (Greenland 1991, Kudenchuk 1996, Maynard 1997, Hochman 1999, 
Hanratty 2000, Rosengren 2001), mostly because women are older and 
have more co-morbidity. In addition, this difference seems to be present 
only in younger patients (Johansson 1984, Vaccarino 1999, Rosengren 
2001) and is partly due to the fact that men with MI tend to die early 
outside hospital (Rosengren 2001, Macintyre 2001). According to 
Framingham data, women are more likely to manifest coronary heart 
disease as unstable angina, whereas men develop manifest MI to a higher 
degree than women (Lerner 1986). 
Diabetes mellitus and acute coronary syndromes 
In many studies diabetes mellitus (DM) emerges as an important risk factor 
influencing clinical presentation, course and prognosis of ACS. While the 
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prevalence of diabetes is 3 to 6% in the general Swedish population 
(Andersson 1991, Larsson 1995, Lidfeldt 2001, Eliasson 2002), 20 to 25% 
of patients with myocardial infarction have known diabetes (Abbud 1995, 
Lundberg 1997, Löwel 2000, Malmberg 2000, Tenerz 2001). An even 
greater proportion of the MI patients have previously undiagnosed diabetes 
or impaired glucose tolerance when arriving in the coronary care unit 
(Norhammar 2002). Indeed, recent studies have shown that only about a 
third of the patients with acute MI have normal glucose tolerance 
(Norhammar 2002). 
Diabetes is associated with markedly increased risk of myocardial 
infarction (MI) and cardiovascular mortality in diabetic compared with 
non-diabetic subjects (Lapidus 1985, Ulvenstam 1985, Krolewski 1987, 
Abbott 1988, Barrett-Connor 1991, Manson 1991, Lehto 1994, Abbud 
1995, Hanefeld 1996, Herlitz 1996, Chun 1997, Mukamal 1997, Adlerberth 
1998, Haftner 1998, Miettinen 1998, Vilbergsson 1998, Lee, 2000, Hu 
2002, Kanaya 2002, Löwel 2000, Malmberg 2000, Yusuf 2004). In 
addition, women with diabetes seem to be more vulnerable than men with 
diabetes (Abbott 1988, Barrett-Connor 1991, Lehto 1994, Chun 1997, 
Benderly 1997, Mukamal 1997, Miettinen 1998, Lee, 2000, Malmberg 
2000, Yusuf 2004) although findings have not been entirely consistent 
(Abbud 1995, Krolewski 1987, Vilbergsson 1998, Löwel 2000). However, 
a recent meta-analysis demonstrated this to be due to more risk factors in 
diabetic women (Kanaya 2002). 
Whereas mortality from coronary heart disease has declined in the general 
Western population during the last decades, the pattern has not been 
consistent in the diabetic population. Among diabetic men a smaller 
reduction (Gu 1999), or no decrease at all (Chun 1997), was reported, while 
in women with diabetes coronary mortality was unchanged (Chun 1997) or 
even increased (Gu 1999). Accordingly, the difference in coronary heart 
disease (CHD) morbidity and mortality between diabetic and non-diabetic 
individuals seems to have increased more in women than in men. 
Patients with diabetes are often characterized by a worse cardiovascular 
risk factor pattern, including obesity, high blood pressure (BP) and 
disturbed lipid levels. However, few studies have compared risk factors in 
men and women with diabetes or investigated to what extent the major 
CHD risk factors contribute to the risk of MI in women with diabetes 
(Barrett-Connor 1991). 
Acute CHD do not always manifest with typical symptoms. Diabetic 
patients often present with less chest pain at admission to hospital (Culic 
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1992, Gustafsson 2000, Yaccarino 2000), and similar or lower rates of ST-
elevation (Gustafsson 2000, Vaccarino 2000, McGuire 2000), compared 
with non-DM patients. In addition the proportion of patients hospitalised 
with unstable angina has increased and now form an important subset of 
patients with ACS (McGovern 2001). Studies of women, diabetes and 
CHD have, so far, mostly focused on acute MI. Few studies have analyzed 
men and women with diabetes across the whole range of ACS. 
The immune system, atherosclerosis and inflammation 
It is well known that patients with diabetes have more atherosclerosis than 
non-diabetic subjects. Atherosclerosis is a process in which inflammation 
plays an important role (Libby 2002). Because lipids are insoluble in water, 
they can only circulate if they are bound in lipoprotein complexes. These 
consist of a central core of non-polar lipids, primarily triglycerides and 
cholesteryl esters, and a surface built up of a phospholipid monolayer 
including free cholesterol and apoprotein molecules. Low-density-
lipoprotein- (LDL) cholesterol is the main cholesterol-bearing lipoprotein, 
with apoprotein B-100 as the characteristic feature at the surface (Howard 
1993). Circulating LDL-cholesterol can enter the vessel wall, where it may 
become oxidized. Oxidized LDL (oxLDL) has been suggested to be a key 
antigen in the development of atherosclerosis by stimulating monocytes to 
infiltrate into the vessel intima; these then differentiate into macrophages, 
which produce cytokines, oxygen radicals and heat shock proteins, and 
form foam cells (Hansson 1997). 
Oxidation of LDL-cholesterol involves oxidation of polyunsaturated fatty 
acids in the lipoprotein core, with formation of highly reactive breakdown 
products such as malondialdehyde, MDA (Esterbauer 1990). MDA may 
form covalent adducts with lysine and histidine residues in apo-B100, 
making them highly immunogenic (Palinski 2000). Similarly immunogenic 
so-called neoepitopes may result from oxidation by other agents, such as 
cupper ions, which, besides MDA, are widely used in laboratory situations. 
Immunogenic epitopes may also result from non-enzymatic glycation of 
LDL (Palinski 2000). 
Hyperglycemia increases non-enzymatic glycosylation, whereby glucose 
molecules bind to amino groups on different structures, forming advanced 
glycosylation end products (AGE). Also, hyperglycemia enhances free 
radical formation by autooxidation. Furthermore, glucosylation of vascular 
structural proteins may alter the characteristics of the vessel wall itself and 
influence its interaction with circulating plasma constituents. (Lyons 1993). 
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Modified lipoproteins, especially oxLDL, have been the focus of much 
research in the last decade (Hulthe 2004). Several studies support the 
hypothesis that oxLDL is involved in the development of atherosclerosis in 
humans. However, it is not well established whether the immune response 
is predominantly pro- or atherogenic in man. Immunization of animals with 
oxLDL seems to protect against atherosclerosis (Hulthe 2004). Even so, 
unspecific antibodies have been shown to reduce atherosclerosis in animal 
models, making the interpretation of these results difficult. 
Antibodies against oxLDL have been demonstrated in human and rabbit 
atherosclerotic lesions (Ylä-Herttuala 1994). Immunization of apoE knock­
out mice with homologous plaque homogenates or MDA-modified LDL 
resulted in reduced development of atherosclerotic lesions (Zhou 2001). 
Furthermore, increased levels of antibodies against oxLDL were predictive 
of MI (Puurunen 1994) and progression of carotid atherosclerosis (Salonen 
1992) in men. However, in other studies no association with cardiovascular 
events (Uusitupa 1996), carotid intima-media thickness (Uusitupa 1996, 
Hulthe 1998) or the extent of coronary atherosclerosis (van de Vijver 1996) 
was found. 
The demonstration of antibodies against oxLDL indicates that lipid 
peroxidation may occur in vivo. Lipid peroxidation may be increased in 
diabetes, as hyperglycaemia influences the production of free radicals by 
auto-oxidation of glucose and the formation of advanced glycation end-
products and superoxide radicals (Oranje 1999). Previous studies have 
reported elevated levels of antibodies against modified LDL in diabetic 
compared with non-diabetic subjects (Bellomo 1995, Festa 1998, Leinonen 
1998, Mäkimattila 1999), but studies have not been consistent (Uusitupa 
1996, Lopes-Virella 1999). Antibodies against modified LDL were recently 
reported to be elevated in diabetic subjects with macrovascular disease, but 
not in diabetic subjects without macrovascular disease or in healthy 
controls (Hsu 2002). 
C-reactive protein (CRP) is considered to be a sensitive marker for 
systemic inflammation. Its concentration is mainly determined by the liver 
in response to cellular cytokines (Pepys 1995). CRP is associated with 
several CVD risk factors (Mendall 1996, Rohde 1999) and is also an 
independent risk factor for diabetes (Pradhan 2001, Freeman 2002, Hu 
2004), stroke (Rost 2001), and cardiovascular disease in both men and 
women (Ridker 1997, Ridker 1998). Furthermore, Ridker reported CRP to 
be a stronger risk factor than LDL-cholesterol for first cardiovascular 
events in women (Ridker 2002). 
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Risk factors for the development of diabetes 
With increasing incidence and prevalence of type 2 diabetes throughout the 
world (King 1998, Wild 2004), finding strategies to prevent diabetes and its 
complications has developed into a major issue, and perhaps even more in 
women than in men, because they seem more vulnerable to the devastating 
effects of diabetes (Barrett-Connor 1991, Miettinen 1998, Gu 1999, 
Malmberg 2000). Previous prospective studies of different populations 
have reported several factors to be important for the subsequent 
development of diabetes, such as increased body mass index (BMI) 
(Medalie 1975, Balkau 1985, Ohlson 1988, Lundgren 1989, McPhillips 
1990, Charles 1991, Mykkänen 1993, Perry 1995, Haffher 1997, Carey 
1997), high waist/hip ratio (WHR) (Ohlson 1988, Lundgren 1989, 
Mykkänen 1993), high blood pressure (Ohlson 1988, McPhillips 1990, 
Mykkänen 1993, Haffner 1997), an unhealthy lifestyle (Hu 2001), 
dyslipidemia (Balkau 1985, McPhillips 1990, Mykkänen 1993, Perry 1995, 
Haffner 1997), insulin resistance (Lillioja 1993, Haffner 1997), and high 
glucose- and insulin levels in the fasting state and/or after an oral glucose 
tolerance test (Balkau 1985, Ohlson 1988, Lillioja 1993, McPhillips 1990, 
Charles 1991, Mykkänen 1993). 
More than half of these studies did not give further details on, or did not 
even include, women. Studies which did assess women were a study of 
middle-aged Mexican-Americans and non-Hispanic whites from Texas 
(Haffner 1997), two studies of elderly subjects in California (McPhillips 
1990) and Finland (Mykkänen 1993), one earlier study from Sweden 
(Lundgren 1989) and the American Nurses Health Study (Carey 1997, Hu 
2001). However, the 18-year follow-up of the present study of risk factors 
for incident diabetes is the longest described so far. 
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GENERAL AIM 
To explore the reason why women with diabetes lose the female protection 
against MI, by investigating cardiovascular risk factors, markers of 
inflammation, early predictors for future development of diabetes and 
clinical manifestations in diabetes and coronary heart disease. 
SPECIFIC AIMS 
• To estimate the cardiovascular risk factor burden in women with 
diabetes, MI or both compared with healthy women, and to 
investigate to what extent the differences in risk factors might 
explain the increased risk of MI and complication rate in women 
with diabetes. (Paper I) 
• To explore the association between the immune response, as 
measured by antibody titers to malondialdehyde-treated LDL, CRP, 
a marker of inflammation, and diabetes mellitus and MI in women. 
(Paper II) 
» To investigate risk factors for the development of diabetes mellitus 
in middle-aged women. (Paper III) 
• To investigate the influence of diabetes mellitus on clinical 
presentation, in-hospital complications and outcome in women and 
men with acute coronary syndromes (ACS). (Paper IV) 
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SUBJECTS AND METHODS 
The Göteborg myocardial infarction register 
The Göteborg MI Register started in 1968 with the aim to register all 
events of MI and deaths from CHD in subjects below 65 years of age in the 
city (Elmfeldt 1975). Specially trained personnel scrutinized patient and 
diagnosis lists of the emergency department, and the medical wards, several 
times every week. Patients with suspected or obvious MI were recorded 
and followed up until a definite diagnosis was verified or refuted. An MI 
was considered to have occurred when at least two of the three criteria 
chest pain, enzyme leakage and typical ECG changes were fulfilled. For the 
years 1988-1998 enzyme changes defining MI were serial serum aspartate-
aminotransferase (ASAT) >0.7 jikat/1, serial creatine kinase (CK) >3.3 
(ikat/1 or serial creatine-kinase MB subunit mass (CKMB) >15 jj.g/1. The 
methods of registration and diagnosis of MI are described in detail 
elsewhere (Wilhelmsen 1997a). A validation of the register showed that 
less than 10% of the surviving patients with a clinical MI were missed by 
the registration procedure (Elmfeldt 1975). The register continued to run 
until 1996. 
Study I 
Mi-women with and without diabetes 
All surviving women below the age of 65 years, who had been hospitalised 
with an MI according to the Göteborg MI Register in any of the two 
Göteborg hospitals in 1994 to 1996, were invited to participate in the study. 
The prevalence of diabetes was not known before examination. As there 
turned out to be only 19 eligible women with both diabetes and MI in the 
original cohort, diabetic women hospitalised due to MI in 1993 and 
diabetic women hospitalised with MI at the two neighbouring hospitals 
during the same time interval were also invited. Table 2 shows numbers of 
invited and participating women. In all, 29 women with diabetes and MI 
and 64 non-diabetic women with MI participated in the study. The time 
interval between the MI and examination varied between 2 and 42 months. 
Control women with and without diabetes 
In 1985, 1990 and 1995 random samples of the Göteborg population were 
examined within the framework of the WHO-MONICA project, a 
multinational study initiated to register risk factors and trends in the 
incidence of cardiovascular disease in the general population (Wilhelmsen 
1997b). In each of these screenings 375 (75%), 432 (72%), and 470 (67%), 
respectively, of the originally invited women, 45 - 64 years of age were 
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examined. Women with diabetes participating in any of the three 
MONICA-screenings (n=28) were included in the study. Together with 
diabetic women non-consecutively enrolled from the hospital register of 
outpatients (n=16), and from a neighbouring general practitioner (n=2), 
they constituted the diabetic controls (n=46). A random fourth of the 
women invited to the 1995 MONICA-screening were selected to constitute 
the group of healthy controls (n=193), of whom 125 (64.8%) accepted to 
participate. None of the control women had a history of previous MI or 
clinical signs of ischaemic heart disease, and all had a nonnal resting ECG. 
The participants arrived to the examination after an overnight fast. Present 
and past health status, smoking habits and medication were recorded by 
way of questionnaires. Height, weight and circumference of the waist and 
hip were measured with the subject standing, in light clothing, to allow 
calculation of body mass index and waist to hip ratio. Blood pressure was 
measured in the sitting position twice, after at least 5 minutes rest, to the 
nearest 2 mmHg. Venous blood samples were drawn for analyses of 
haemoglobin (HbAic), total cholesterol, high-density lipoprotein (HDL) 
cholesterol and triglycerides (TG); all analyses were performed the same 
day. Further blood samples were collected and serum was kept frozen in -
70°C. Glycated haemoglobin (HbAlc) was analysed with a HPLC method, 
normal range 3.6 to 5.3%. Fibrinogen was analysed according to the Clauss 
method (Clauss -57). 
Table 2. Numbers of participating women with diabetes and MI (DM+MI), MI but 
not diabetes (Ml not DM), diabetes but not Ml (DM not Ml) and healthy 
controls. (Paper I) 
DM+MI DM not Ml Ml not DM controls total 
Eligible, n 19 7 97 193 376 
Died before 
screening, n(%) 
3(15.8) 14(14.4) 17 
Refused, n 2 21 19 68 110 
Non-consecutively 
identified, n 
15 15 
Included, n 29 46 64 125 264 
Questionnaire only, n 6 2 10 5 23 
Examined, n(%) 23(59.0) 44(65.7) 54(55.7) 120(62.2) 241(60.9) 
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Study II 
The participants of Study II constitute a subsample of the cohort in Study I, 
because blood samples were not available in all. Altogether, 18 women 
with diabetes and MI, 46 non-diabetic women with MI, 35 diabetic women 
without MI and 70 healthy controls were included in Study II. IgM and IgG 
antibodies against MDA-LDL were analysed with a solid phase ELISA 
technique (Hulthe 1998). CRP was determined with a highly sensitive 
immunometric assay (Oy Medix Biochemia AB, Kauniainen, Finland), 
modified at the Wallenberg laboratory, Sahlgrenska University Hospital in 
Göteborg. 
Study III 
A random population sample of 1351 women, aged 39-64 years, without 
previous CVD or diabetes, participated 1979-81 in a screening 
investigation with questionnaires, a physical examination and blood 
sampling. The questionnaires included questions about present and past 
health status, smoking habits, physical activity, education, alcohol intake 
and menopausal state. The participants were examined in the morning after 
an overnight fast. Weight and height were measured and BMI was 
calculated. Blood pressure was measured after 5 minutes rest with the 
subject seated. Serum cholesterol concentrations were measured according 
to Cramér (Cramér 1959) and concentrations of serum triglycerides 
according to Carlsson (Carlsson 1959). There were no data on blood-
glucose, HDL- or LDL-cholesterol from the first screening. 
Follow-up procedures 
By 31 December, 1997, 150 of the initially participating women had died. 
Among the 1201 surviving women, 875 (73%) returned for a second 
examination between 1997 and 1998, 18 years after the first screening. The 
procedures for the second screening were similar to those of the first 
examination. 
Of the women returning for a second examination, 41 had been diagnosed 
with diabetes during the intervening period. Five more women were 
diagnosed at the examination, presenting with a fasting plasma glucose 
level of > 8.0 mmol/1, and confirmed at clinical follow-up. In addition, the 
Swedish national register on deaths due to specific causes from 1980 to 
1998 and the Swedish hospital discharge register were matched against a 
computer file of the women in the study to identify diabetes among those 
who did not participate in the second examination. In this manner we 
identified diabetes in another 27 women with a principal or secondary 
diagnosis of diabetes during follow-up. Twenty of these women were still 
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alive but did not take part in the second screening, and seven women had 
died. Altogether, among the 1351 women participating in the initial 
screening, 73 women (5.4%) were diagnosed with diabetes during the 
follow-up period up to 1999 (Fig. 1). 
1413 
875 
1351 
150 
dead 
7 diabetes 
46 diabetes 
20 diabetes 326 non-
participants 
4 prior coronary disease 
34 missing lipid values 
Participants 1997-1998 
Participants 1980 
At risk 
1 diabetes diagnosed 
within two years 
23 diabetes prior to first 
investigation 
Figure 1. Participants in the study of risk factors for incident diabetes in 
middle aged women. (Paper III) 
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Study IV 
Onehundred-three hospitals in 25 countries in Europe and the 
Mediterranean basin participated in this study of consecutive patients 
presenting with symptoms compatible with ACS. All patients were 
categorised according to the primary diagnosis by the attending physician, 
based on the initial electrocardiographic pattern, i.e. ACS with ST-
elevation, ACS without ST-elevation or ACS with an undetermined 
electrocardiographic pattern. When the definite diagnosis of unstable 
angina or MI was confirmed, the patient was included in the study and a 
full case report form was filled out. 
The case report form comprised data on demographics, previous history 
and cardiovascular risk factors, presenting symptoms, electrocardiographic 
findings, medical therapy, coronary angiography, evaluation of left 
ventricular function, reperfusion and intervention therapy, in-hospital 
complications, discharge status and 30-day follow-up status. The attending 
physician classified the discharge diagnosis as Q-wave MI, non- Q-wave 
MI, or unstable angina pectoris. The enrolment period ran between 4 
September, 2000 and 31 May, 2001. 
In all, 10484 patients were included. For the purpose of the present study, 
patients aged more than 80 years (n=1187) were excluded, as elderly 
patients often have concomitant disease not detailed in the register, leaving 
9297 patients who form the study population of this analysis. Diabetes was 
present in 2182 (23.5 %) subjects, of whom 806 (36.9 %) were women. 
The prevalence of diabetes was 21.1 % in men and 28.7 % in women (Fig 
2). 
Definition of diabetes 
Study I and II 
Diabetes was defined as an affirmative response to the question "Did a 
doctor tell you that you have diabetes?" and/or antidiabetic treatment with 
diet, oral agents and/or insulin. No systematic testing for previously 
unknown diabetes was performed. Age <35 years at diagnosis or starting 
continuous insulin treatment within one year of diagnosis was defined as 
type 1 diabetes, all other were defined as type 2. However, due to the small 
number of women with diabetes and MI, type 1 and type 2 diabetes were 
not separated in the analyses. 
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ACS < 80 years 
n=9297 
ACS > 80 years 
n=1187 
Women 
n=2809 
No ACS 
n=3787 (26.5 %) 
ACS 
n=10 484 
Men 
n=6488 
Logged 
n=14 271 
DM 
n=1376 
no DM 
n=5112 
DM 
n=806 
no DM 
n=2003 
Figure 2. Participants of the Euro heart Survey ACS. (Paper IV) 
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Study III 
Women were defined as diabetic if they had been diagnosed by a doctor 
during follow-up, or if they presented with a fasting plasma glucose level 
of > 8.0 mmol/1 at the second examination, with diabetes confirmed at a 
clinical follow-up. In non-participants of the second screening, those were 
defined as diabetic who were registered with a principal or secondary 
diagnosis of diabetes [ICD-8 and ICD-9 code of 250 and ICD-10 code El 1 
(from 1997)] in the Swedish hospital discharge register, or the Swedish 
national register on deaths due to specific causes from 1980 to 1998. 
Only diabetes diagnosed more than two years after the first screening was 
defined as new onset diabetes. Since the women who developed diabetes 
were middle-aged at diagnosis, they were assumed to have type 2 diabetes. 
Study IV 
A participant was defined as having diabetes if he or she reported 
previously diagnosed diabetes, or if diabetes was stated in previous or 
present medical charts and documents. Furthermore, patients who were not 
reporting diabetes at admission, but were discharged with oral 
hypoglycaemic agents or insulin, were presumed to have had diabetes also 
before the index event. Biochemical confirmation of diabetes status or any 
systematic testing for previously undiagnosed diabetes was not performed 
in the study. 
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STATISTICAL PROCEDURES 
All analyses were performed with SAS statistical software, version, 6.12 in 
Study II and version 8e in the other studies. Means and proportions were 
calculated with standard methods. 
Study I 
The differences between groups with respect to continuous variables were 
tested for statistical significance using the general linear model procedure 
(GLM). In the analyses of anthropometric data, lipids and hormones, only 
comparisons between non-diabetic women with MI and the healthy 
controls were age adjusted, because the mean age was similar in diabetic 
women with and without MI. Multiple logistic regression models were used 
to assess the independent association of risk factors, with MI as the 
dependent variable, in women with and without diabetes separately. Only 
diabetic women with MI who were examined (=23) were included in the 
multivariate analysis. Furthermore, smokers and ex-smokers were 
combined into one category in these models because many of the ex-
smokers stopped smoking after MI. A p value less than 0.05 was 
considered significant. 
Study II 
Age-adjusted means were determined by analysis of covariance with age as 
covariate and presented as means + 95% confidence intervals (CI). As CRP 
levels were not normally distributed, non-parametric Spearman's 
correlation test was used to test correlations between CRP, LDL-antibodies 
and CVD risk factors. Multiple regression was used to test the association 
between diabetes and MI on the one hand and antibody titers and CRP on 
the other with respect to background variables such as BMI, WHR, SBP, 
TG, HDL-cholesterol, medication and menopause. 
Study III 
In the cross-sectional analysis of base line variables age-adjusted means 
(SD) or proportions were compared using the general linear model 
procedure (GLM). In the prospective part of the study age-adjusted 
proportional hazards regression analyses were used to calculate hazard 
ratios (HR). As the date of diagnosis of diabetes was unknown in women 
identified by the hospital discharge register only, the date for the first 
hospitalisation was used instead. However, because the date of diagnosis is, 
in itself, an approximation, with an unknown period of time of either 
asymptomatic or undiagnosed diabetes, the proportional hazards model 
may not be appropriate. Accordingly, we also repeated all analyses using 
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multiple logistic regression models instead, with diabetes as the dependent 
variable. Results were virtually identical whether logistic regression or 
proportional hazards models were used, and the proportional hazard models 
were kept throughout. 
In the multiple regression analyses baseline smoking was entered as never, 
former, or current smoking of <15 cigarettes/day or >15 cigarettes/day. 
Menopause was coded as 1 for yes and 0 for no. BMI, SBP, serum 
cholesterol and TG were entered as continuous variables in the regression 
analysis of baseline variables. In the prospective study these variables were 
categorised with the aim of forming clinically meaningful cut-off limits. 
When BMI, SBP and serum TG were introduced into the models as 
potential confounders they were, however, entered as continuous variables. 
Results were essentially identical whether serum TG were log-transformed 
or not, and accordingly only non-transformed values were used throughout. 
Leisure time physical activity was entered as sedentary (level 1) versus 
non-sedentary (levels 2-3). With respect to education two dummy variables 
were created (secondary and college/university) with compulsory education 
as reference. 
Study IV 
Means (SD) and proportions were calculated with standard methods. The 
associations between diabetes and presentation, complications and 
outcome, were tested with Mantel-Haenszel Chi-square tests for men and 
women separately. Age adjusted odds ratios, OR, with 95 % confidence 
intervals (CI), for differences in proportions between diabetic and non-
diabetic subjects were calculated by logistic regression for men and women 
separately. To determine whether differences in clinical presentation, 
complication and outcome between subjects with and without diabetes 
were due to differences in baseline characteristics, we adjusted for these by 
multiple logistic regression models in men and women separately. 
Variables that were included in the models were age, smoking, body mass 
index, hypertension, prior congestive heart failure (CHF), renal failure, 
previous drug use (ASA, beta-blockers and statins), previous angina 
pectoris, prior MI, and prior revascularisation. Possible interactions 
between sex and diabetes were tested with the interaction term 
(sex*diabetes) introduced in the logistic regression model with the relevant 
presenting or discharge diagnosis as the dependent variable. To investigate 
the effect of sex, age, and diabetes, on mortality, patients were divided in 
three subgroups based on age <65, 65-74, and > 75 years, and odds ratios 
were calculated with a logistic regression model in men and women 
separately. 
25 
RESULTS 
Study I 
Data on age, smoking habits, menopause, physical activity, diabetes 
duration and metabolic control as well as antihypertensive and lipid-
lowering therapy in the participants of Study I are shown in Table 3. Mean 
age was lower among the healthy control women, because, in the MONICA 
study, equal proportions of women in the 10-year age groups 45 to 54 and 
55 to 64 years were included. Among the patients who were included, 4 
(13.8%) of the women with both diabetes and MI, 10 (15.6%) of the 
women with MI but no diabetes, and 6 (13.0%) of the diabetic women 
without MI, respectively, were younger than 50 years of age, compared to 
30 (24.0%) among the control women. 
Table 3. Age, smokinghabits, menopausal state, metabolic control and medication in 
participants of Study I. (mean, 95% CI, or %) 
Base of variables DM+MI 
n=23 
DM not Ml 
n=44 
Ml not DM 
n=54 
controls 
n=12Q 
Age, years 56.3 
(54.0, 58.7) 
55.9 
(54.0, 57.8) 
56.4 
(54.5, 58.3) 
54.4 
(53.4, 55.3) 
Smokers, % 39.3 23.9 28.6 31.5 
Ex-smokers, % 46.4 26.1 54.0 27.4 
Postmenopausal, % 95.7 84.1 87.3 71.6 
Age at menopause, 
years 
50.4 
(47.8, 53.0) 
49.2 
(47.5, 50.9) 
47.6 
(46.1, 49.1) 
49.3 
(48.2, 50.5) 
Sedentary lifestyle, % 39.3 14.0 20.6 25.7 
Diabetes duration, 
years 
16.3 
(9.8, 22.8) 
15.3 
(11.3, 19.3) 
HbA1c, % 7.83 
(6.98, 8.68) 
7.22 
(6.61, 7.82) 
Treatment with lipid-
lowering agents, % (n) 
65.2(15) 4.5 (2) 54.5 (30) 1.7 (2) 
Treatment with anti­
hypertensive therapy, 
% (n) 
95.7 (22) 43.2(19) 87.0 (47) 12.5(15) 
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Table 4 shows anthropomethric data, systolic and diastolic blood pressure, 
lipid levels, plasma fibrinogen, s-estradiol and sex-hormone binding 
globulin (SHBG). Despite the fact that diabetic women with and without 
MI had similar body mass index, those with a past MI had significantly 
higher waist/hip ratio, markedly elevated serum triglycerides, and low HDL 
cholesterol, indicating pronounced metabolic disturbances. Women with 
MI but no diabetes had intermediate values for waist/hip ratio, triglycerides 
and HDL cholesterol. 
Although 65% of the women with diabetes and prior MI were on lipid 
lowering therapy, the recommended levels of total cholesterol <5.0 mmol/1 
and triglycerides < 2.0 mmol/1 were not achieved by more than 22% and 
27%, respectively (Table 4). Furthermore, a considerably lower proportion 
of the women with diabetes and prior MI had HDL-cholesterol > 
1.0mmol/l, and less than 20 % of the diabetic women with MI had both 
triglycerides < 2 mmol/1 and HDL-cholesterol > 1.0 mmol/1. 
To explore the association of the different risk factors with MI, a multiple 
regression analysis was done with age, waist/hip ratio, systolic blood 
pressure, triglycerides, HDL-cholesterol and smoking as independent 
variables in diabetic and non-diabetic women separately. Because serum 
triglycerides and HDL-cholesterol were strongly correlated (r = -0.45, p < 
0.001), we first performed an analysis with age, wais/hip ratio, systolic 
blood pressure, triglycerides and smoking as independent variables (Table 
5). Smoking (i.e. current and former smoking combined) was 
independently associated with MI, both in women with diabetes, and in 
non-diabetic women. In diabetic women triglycerides were independently 
associated with MI, while waist/hip ratio was independently associated 
with MI solely in women without diabetes. However, when HDL-
cholesterol was entered into the models, the association of serum 
triglycerides with MI disappeared, and the OR for waist/hip ratio in non-
diabetic women was slightly attenuated. The association of smoking with 
MI persisted in both groups (Table 5). 
27 
o 
LO 
CT 
+i 
c 
CD 
0 
> 
"O 
ZJ 
co 
M— 
o 
_co 
c 
ro 
o. 
o 
ti 
ro Q. 
(f) O 
O CM 
s = O C 
es 
o „ 
_ ^r 
o 
c II 
^ C 
Q 
h- o 
Csj P 
ö o 
V 
LO 
o 
o 
*3" 
co 
csi 
co 
"vt" 
h-
o 
o 
o 
ö 
v 
00 
o 
o 
CO 00 
o 
o 
ö 
v 
CO 
CT> 
o 
CO 
CM 
o 
CM 
csi 
CM 
. cd ö? co xf -. 
S c si§°§^s c° S c D  
CM K o OJ T- CO 00 
^ ^ 
0X1 
_ CM O ^ CD 
• CD 
oo q -3-
CM 
! c5 S 
co - °9 
-I co o 
LO 
CM 
LO h-
LO • 
CO 
CO 
Is-
- Is-
LO 
CM 
o • 
LO 
LO ^  00 T-
O °° ^ 1^ 
•T- \P CM £; CD CN| co 
„ • I—; _CM „ 
• LOr-f\iLOoCDcO^ CO • fO T-
•  ^
' 00 
55
CM 
CO CO z—«S Is- CO CM LO 
CO 2 CD 
00 
•c— 
CO T— co O o CO LO T~ 
ö 
•«Nr 1
3
5
 T T— 
O) 
CO 
00 5.
96
 
CO 
CTT T— 1.
27
 
Is-" CT) 1.
87
 
CM 
co" 
co 
LO 3.
25
 
CO 
CT)" 
T— 
ö 
ö 
h-" 49
.7
 
oo CM CO 
5.
96
 
LO T— T— cd co CO 3
.2
5 
CT) O 
o LO, CM T— h- T— CO CM, O 
O 
O 
Is- CO CO 
CM CO o 
O ö ö 
t- co g? ä co 
^ o) °9 LO ^ 
^CM^OCOT-^CO^O^ 
CmCOO^^N COCDN 0^ 
LO 00 00 N O CO 
CM Ö ^ CO 
O 
o 
ö 
v 
CD 
LO 
O 
V 
T-
q 
ö 
r-
h-
^t" CM O 
„ „ •« 
T— ,—v CT s v— Is-
Is- CT) CT) CM CO T~ LO 
N-CO 
1.
69
 
T- CO O CO r- ö CO 
T-" CO 1.
69
 
CT>" Is- CO o" Ö lo" CO co" 
"3- CO CO CM CT o CO 
LO CO T— h- 0^ ö 
-—• 
"•—' 
s
— 
N
—' 
S o> LO O _ . O . LO 
CO®OCOv-.CT)^"0 w  
.co .g .00 _ o 
T— CO N- LO n.i 
 00 . 
I®ci^ 
lo °q 
CM O 
CT . 
o 
'=t 
CM 
LO 
O) 
CD 
a: 
x 
O) 
X 
E 
E 
CL 
CD 
CO 
CD 
X 
E 
E 
CL 
CD 
Q 
O 
E 
E 
o 
0 
w 0 
o 
sz 0 1 
CO 
o 
E 
E 
o 
LO 
VI 
Ô 
0 
"oo 
0 
O jC 
O ^  
cô S 
CT) O 
rS LO 
i § 
E „ 
E 9 T-
2 A 
0 "o 
0 B 
"ö w 
5 -22 
O O 
-j O 
Q Ji-pTO 
CO X CO 
CO p CT 
CO 
CO 
CO 
CO *fc 
"<3-
cq 
CT 
co Is-
o 
ö •^t 
o CO o CM 
CO co" CM CM CO CO 
ö "5t 
o 
CM CO o 
o 
E 
E 
cn 
0 
"O 
"s_ 
0 
O 
>. 
Sp o-
=£ 
o 
E ~ö) 
E c" 
o 0 
cm O) 
o 
v c 
CD "l— JO h- M— 
C0 CL 
O 
TD 
ro i— 
a> 
0 
0 1 
CO 
O 
CD 
X 
CO 
CO 
28 
Table 5. Multiple logistic regression analysis of risk factors associated with 
myocardial infarction (Ml) in diabetic and non-diabetic women with and without 
inclusion of HDL-cholesterol in the analysis. OR=odds ratio. (Paper I) 
Diabetes No diabetes 
n=66 n=172 
unit OR p OR p 
(95%CI) (95% CI) 
HDL-cholesterol 
not included in the 
analysis: 
age 1.0 1.09 0.20 1.04 0.23 
(0.96-1.23) (0.98-1.10) 
WHR 0.1 - 4.22 <0.001 
(2.19-8.13) 
Systolic BP, 5.0 1.18 0.053 
mmHg (1.00-1.39) 
S-triglycerides, 1.0 2.70 0.003 
mmol/l (1.40-5.20) 
Smoking* 1.0 15.35 0.003 3.07 0.009 
(2.46-95.66) (1.32-7.16 
HDL-cholesterol 
included in the 
analysis: 
age 1.0 1.10 0.17 1.06 0.08 
(0.96-1.25) (0.99-1,12) 
WHR 0.1 - >0.3 3.69 <0.001 
(1.75-7.76) 
Systolic BP, 5.0 1.19 0.066 - <0.3 
mmHg (0.99-1.42) 
S-HDL- 0.5 0.30 0.043 0.25 <0.001 
cholesterol, (0.09-0.96) (0.12-0.50) 
mmHg 
S-triglycerides, 1.0 1.73 0.13 0.70 0.19 
mmol/l (0.86-3.47) (0.41-1.20) 
Smoking* 1.0 18.78 0.004 3.43 0.008 
(2.59-136.17) (1.38-8.5) 
*smokers and ex-smoker combined 
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Table 6. IgM and IgG titers of antibodies against MDA-LDL, and CRP levels (age 
adjusted means, 95 % CI). (Paper II) 
DM + Ml 
n = 18 
DM not Ml 
n = 35 
Ml not DM 
n = 46 
controls 
n = 70 
IgM 1.41 1.45 1.42 1.61 
(1.24, 1.58) (1.32, 1.57) (1.31, 1.53) (1.51, 1.70) 
IgG 0.98 1.02 1.07 0.95 
(0.89, 1.06) (0.96, 1.08) (1.02, 1.12) (0.90, 0.99) 
CRP, 7.81 5.30 3.58 1.91 
mg/ml (5.39, 10.22) (3.56, 7.03) (2.05, 5.11) (0.60, 3.21) 
Study II 
Antibody titers and CRP levels in the four groups of women are shown in 
Table 6. Diabetic women with MI tended to have lower IgM titres than the 
controls (p=0.053). Diabetic women without MI and Mi-women without 
diabetes had significantly lower IgM titers to MDA-LDL compared with 
controls (p<0.05). No significant differences in IgG titers were seen 
between diabetic women with MI and controls. However, in Mi-women 
without diabetes, IgG titers were significantly higher (p<0.001) and there 
was a trend of higher titers (p=0.07) also in diabetic women without MI 
than in controls (Table 6). 
Table 7. IgM and IgG titers of antibodies against MDA-LDL, and CRP 
levels in cases (= women with diabetes and / or Ml) and healthy controls 
(age adjusted means, 95% CI). (Paper II) 
cases 
n = 97 
controls 
n = 70 
P 
I gM  1.43 1.61 0.005 
(1.35, 1.50) (1.51, 1.70) 
I gG  1.03 0.95 0.005 
(1.00, 1.07) (0.90, 0.99) 
CRP, mg/l 4.75 2.16 < 0.001 
(3.55, 5.94) (1.29, 3.03) 
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CRP levels were elevated in all three groups of patients compared with 
controls (Table 6). Furthermore, diabetic women with MI had significantly 
higher CRP levels than Mi-women without diabetes (p<0.01). There were 
no significant differences between diabetic women without MI and the two 
groups of women with MI in either antibody titers or CRP levels. 
Accordingly, when the three patient groups were analysed together, defined 
as "cases", they had, overall, significantly higher CRP levels and IgG titers, 
and lower IgM titers, compared with controls (Table 7). Adjustment for 
menopausal state into the analyses of IgG and IgM did not change the 
results, nor did logarithmic transformation of CRP (not shown). 
Table 8. Age adjusted base-line cardiovascular risk factors in women with and 
without diabetes during follow-up [mean (SD) or %]. (Paper III) 
Characteristics at baseline no diabetes 
n = 1278 
diabetes 
n =73 
P 
Age, years (SD) 49.1 (7.3) 51.6(7.3) 0.003 
Menopausal, % 43.8 42.6 0.77 
S-cholesterol, mol/l (SD) 6.15(1.23) 6.23 (1.21) 0.54 
S-triglycerides, mmol/l (SD) 1.07 (0.53) 1.55 (0.75) < 0.001 
BMI, kg/m2 (SD) 24.3 (3.7) 28.0 (5.0) < 0.001 
SBP, mmHg (SD) 134(21) 147 (25) < 0.001 
DBP, mmHg (SD) 84 (11) 90 (12) < 0.001 
Leisure time physical activity, 
% sedentary 
22.7 35.4 0.005 
Occupational activity, 
% sedentary 
29.0 23.2 0.29 
Smoking, % 35.5 35.4 0.99 
Compulsory education only, 62.8 70.0 0.21 
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Study III 
Table 8 shows age-adjusted cardiovascular risk factors at baseline among 
the participating women with and without diabetes at follow-up. Women 
who developed diabetes were older and had significantly higher age-
adjusted BMI, serum triglycerides, and blood pressure at the first screening 
than women who remained free from diagnosed diabetes during follow-up. 
They also reported a more sedentary lifestyle, whereas smoking habits and 
educational level did not differ. 
73 women (5.4%) were diagnosed with diabetes during the 18 years of 
follow-up. Table 9 shows that, as expected, increasing obesity and blood 
pressure resulted in an increasing age-adjusted risk of future diabetes, p for 
trend <0.001. Also, low physical activity significantly predicted diabetes. 
S-triglycerides (TG) carried a steeply increasing age adjusted risk. 
Smoking and total serum cholesterol were not associated with increased 
risk of diabetes. After adjustment for BMI, SBP and physical activity, 
increasing TG level remained a strong and significant risk factor for the 
development of diabetes. 
Table 10 shows basal characteristics in non-participating compared with 
participating women in the second BEDA screening. Women who did not 
take part in the second screening were older, more obese, had higher BP 
and serum triglyceride levels, were smokers and lived a sedentary life to a 
higher degree than non-participants. The HR of diabetes with increasing 
TG level was higher in women with incident diabetes identified only 
through the registers than in women identified at the second screening 
(Table 11). However, the marked increase in risk at slightly elevated TG 
levels was seen in both categories. 
Table 10. Basal characteristics in women participating and not-participating in the 
second BEDA-screening 1997-98. (Paper III) 
Participants 
n=875 
Non-participants 
n=476 
Age, years 48 (47, 48) 51 (51, 52) 
Smokers, % 31 43 
Body mass index, kg/m2 24.2 (23.9, 24.4) 25.2 (24.8, 25.6) 
Systolic blood pressure, mmHg 132 (131, 133) 141 (139, 143) 
S-cholesterol, mmol/l 6.05 (5.97, 6.12) 6.34 (6.29, 6.46) 
S-TG, mmol/l 1.02 (0.99, 1.05) 1.24 (1.18, 1.29) 
Low physical activity, % 20 30 
Compulsory education only, % 60 69 
% or means +. 95% CI 
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Table 11. Multiple adjusted hazards ratio of diabetes by triglyceride levels in women 
with diabetes diagnosed at second screening (n=44) and in women with diabetes 
diagnosed by the Swedish national register on deaths due to specific causes, or the 
Swedish hospital discharge register (n=29)*. Adjustments were made for age, BMI, 
and SBP. (Paper III) 
Diagnosis at 2nd screening Diagnosis by register only 
HR (95% CI) HR (95% CI) 
n=44 n=29 
S-triglycerides, mmol/l 
<1.0 1.00 1.00 
1.0-1.4 2.70(1.25-5.86) 4.29(1.31-14.01) 
1.5-1.9 3.94(1.67-9.34) 5.30(1.46-19.26) 
>2.0 2.49(0.75-8.19) 10.47(2.93-37.39) 
*Of the 29 women identified by the Swedish hospital discharge register, 
2 particpated at the second screening. 
Study IV 
Basal characteristics 
Baseline characteristics in men and women with and without diabetes are 
shown in Table 12. As expected, patients with diabetes were older, and 
women were older than men. More men than women were smokers, 
irrespective of diabetes. Hypertension, obesity, a history of prior stroke, heart 
failure, MI, angina pectoris and prior revascularisation were all more common 
in men and women with diabetes. 
At admission 25% of men and 19% of women with diabetes were on diet 
treatment only, 48 and 46%, respectively, were treated with oral 
hypoglycaemic agents, 5%, a similar proportion of men and women, with oral 
hypoglycaemic agents in combination with insulin, and 22 and 29%, 
respectively, of men and women with diabetes were treated with insulin only. 
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Clinical presentation 
Clinical presentation, symptoms at admission and complications during 
hospital stay are shown in Table 13. The absolute majority of patients 
presented with typical chest pain at admission. However, significantly 
fewer diabetic than non-diabetic women stated typical chest pain, whereas 
there was only a small and non-significant difference among men. Men 
with diabetes were less likely to present with ST-elevation than non-
diabetic men, whereas there was no difference in women when age was 
taken into account. Non-ST-elevation ACS was slightly less frequent in 
diabetic women. 
Complications in hospital 
All forms of heart failure were more likely to occur in diabetic than non-
diabetic patients, especially in women (Table 13). Except asystole during 
hospital stay, other arrhythmias or mechanic complications, as well as 
recurrent ischemia, bleeding complications, and stroke, did not differ by 
sex or by diabetes. 
Investigations and treatment. 
85% and 77% (p<0.001) of diabetic and non-diabetic women, and 78% and 
73% respectively (p<0.001) of men, performed a stress test during hospital 
stay. Angiographic investigation and findings by sex and diabetes are 
shown in Table 14, and interventions are shown in Table 15. 
Discharge diagnosis and mortality 
The impact of diabetes on the final diagnosis differed in men and women 
(Table 16). More women with than without diabetes, but fewer diabetic 
than non-diabetic men, were discharged with a definite diagnosis of MI. 
Furthermore, more diabetic than non-diabetic women developed a Q-wave 
Ml, whereas the reverse was found in men. Accordingly, unstable angina 
was a more common discharge diagnosis in diabetic compared with non-
diabetic men, whereas the opposite was true for women. 
In-hospital mortality was significantly higher in diabetic than non-diabetic 
women, (7.3% vs 3.8%, pO.OOl) (Table 16), irrespective of age group (Fig 
3), whereas the difference was smaller and not significant in men (4.0% vs 
3.3%, p=0.20). Thirty-day mortality was increased in diabetic compared 
with non-diabetic patients irrespective of sex (8.4% vs 4.6%, p<0.001 in 
women and 6.0% vs 4.1% p=0.002 in men, respectively) (Fig 4). 
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Figure 3. In-hospital mortality (%) by age group in men and women 
participating in the European Heart Survey ACS. 
OR = odds ratios. Unfilled bars = patients without diabetes. 
Filled bars=patients with DM. * p<0.05 
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Figure 4. 30-day mortality (%) by age group in men and women 
participating in the European Heart Survey ACS. 
OR=odds ratios. Unfilled bars=patients without diabetes. 
Filled bars=patients with diabetes. * p<0.05 
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Multiple adjustments for differences in base-line variables 
When differences in smoking, hypertension, BMI, heart failure, renal 
faiulure, prior medication, and prior disease were taken into account, 
women with diabetes significantly more often presented with ST-elevation 
ACS, developed Q-wave MI, and had higher in-hospital mortality than 
non-diabetic women, whereas the lower risk in diabetic men was no longer 
significant (Table 17). The interaction tests between sex, diabetes and ST-
elevation at admission, development of Q-wave-MI and in-hospital 
mortality, respectively were significant (Table 17). Including ST-elevation 
or Q-wave MI in the multiple regression did not change the OR for 
mortality either in women or in men. Diabetes increased multiple adjusted 
OR for 30-d mortality in both men and women (Table 17). 
Table 17. Odds ratios for ST-elevation-ACS, Q-wave Ml, and iri-hospital mortality in 
men and women with and without DM hospitalised due to ACS. (Paper IV) 
Men Women 
OR 
multiple 
adjusted 
OR 
multiple 
adjusted 
p for interaction 
DM and sex 
ST-elevation 
ACS 
0.99 
(0,86-1.14) 
1.46 
(1.20- 1.78) <0.001 
Q-wave Ml 0.99 (0.85-1.15) 
1.61 
(1.30- 1.99) <0.001 
Hospital 
mortality 
1.13 
(0.76- 1.67) 
2.13 
(1.39-3.26) 0.021 
30 d mortality, 
% (n) 1.44 (1.04-2.0) 
1.95 
(1.31 -2.89) 0.13 
OR were adjusted for age, smoking, BMI, heart failure, renal failure,hypertension, 
prior drug use and prior disease. 
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DISCUSSION 
Diabetes prevalence 
The proportion of subjects with diabetes is considerably higher among 
patients with MI/ACS than in the general population. Whereas the 
prevalence of diabetes in the Nordic countries is reported to be 2 to 6 % 
(Andersson 1991, Tuomilehto 1991, Larsson 1995, Vilbergsson 1997, 
Lidfeldt 2001, Eliasson 2002), 16.4% of the women with MI in Study I, 
and 21.2% of the men and 28.7% of the women in the study of ACS 
patients (Study IV) were diabetic. These figures are in accordance with 
previous studies concerning patients with MI (Abbott 1988, Abbud 1995, 
Lundberg 1997, Tenerz 2001, Norhammar 2003) and ACS (Malmberg 
2000, McGuire 2000), and patients undergoing coronary angiography 
(Taubert 2003). Furthermore, a considerable proportion of patients with MI 
have previously undiagnosed diabetes and impaired glucose tolerance 
(Norhammar 2002, Rathmann 2002), leaving only a third of MI patients 
with normal glucose tolerance (Norhammar 2002). Moreover, previous 
studies have shown that the proportion of unrecognised diabetes was 
similar to that of known diabetes in patients undergoing coronary 
angiography (Taubert 2003) and in general population samples (Lidfeldt 
2001, Eliasson 2002, Rathmann 2003). 
Diabetes and coronary heart disease 
Although the absolute hazard of MI in women is low until older age 
(Rosengren -01), a history of diabetes mellitus or previous MI greatly 
increases the risk. Women with diabetes are thereby more similar to men, 
with and without diabetes, than non-diabetic women (Barrett-Connor 
1991). 
In previous studies women with diabetes have been compared with non-
diabetic women or diabetic men with respect to the prevalence of CVD risk 
factors (Koivisto -96, Vilbergsson -98), and to risk factors for CVD 
morbidity and mortality after MI (Löwel -00) and CABG (Sprecher -00). 
There are also several reports on CVD risk factors in diabetic compared 
with non-diabetic subjects, with data on men and women pooled together 
(Krolewski 1987, Hanefeld 1996, Turner 1998, Uusitupa 1993). However, 
there are few studies, if any, comparing CVD risk factors in diabetic and 
non-diabetic women with and without a prior MI. 
Clinical characteristics of the women with MI in the present study were 
similar to those of women enrolled in previous Swedish investigations on 
women and MI (Johansson 1988, Engström 2000, Al-Khalili 2002). That 
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is, women who have sustained an MI are characterized by a high proportion 
of diabetes, obesity, hypertriglyceridemia and low HDL cholesterol levels, 
whereas total serum cholesterol is not markedly higher than in healthy 
controls. 
ACS 
In recent years, the focus with respect to acute coronary disease has shifted 
from only MI to the whole spectrum of acute coronary syndromes, 
including MI with and without ST elevation, as well as unstable angina. 
The different forms of ACS are all the same disease, but with different 
symptoms, clinical signs and implications. In addition, patients with 
unstable angina now form an important subset of the ACS population 
(McGovern 2001). The present study IV, based on a recently investigated 
large sample, adds information about the clinical manifestation and short-
term prognosis in men and women across the whole range of ACS. 
Most studies dealing with diabetes and ACS have investigated patients with 
MI only, and it is often reported that diabetic patients with ACS less 
frequently present with ST-elevation at admission (Gustafsson 2000, 
Vaccarino 2000, McGuire 2000). However, in prior studies the men and 
women were not analysed separately and, accordingly, the results might 
reflect the higher proportion of men among the patients (Gustafsson 2000, 
McGuire 2000), or rates that were not adjusted for other baseline variables 
(Vaccarino 2000). The GUSTO lib study found diabetes to be associated 
with an increased likelihood of ST-elevation at admission, however, a 
possible interaction with sex was not reported (Hochman -99). 
Atypical presentation, which is more common in diabetic women, might 
contribute to a misjudgement of the severity of disease in patients with 
diabetes and consequently result in less intensive treatment and worse 
prognosis. This dilemma is supported by previous studies showing that 
diabetic patients with MI receive less treatment with thrombolysis, beta-
blockers and aspirin (Löwel 2000, Norhammar 2003, Gitt 2003), even 
though the benefit of those treatments are as well established in diabetic as 
in non-diabetic patients (Löwel 2000, Norhammar 2003, Gitt 2003). 
Although patients with diabetes do not develop larger infarctions (Lehto 
1994, Miettinen 1998, Melchior 1999), heart failure is more common in 
subjects with than without diabetes (Lehto 1994, Melchior 1999). 
Furthermore, diabetic women are more likely to develop heart failure than 
men with diabetes after MI (Vaccarino 2000, Crowley 2003). This finding 
is underscored by the present study, where decreased ventricular function 
(LVEF < 40%) was much more common among the patients with diabetes, 
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particularly in the women. A contributing factor might be the more severe 
and diffuse coronary atherosclerosis reported in diabetic women (Natali 
2000, Pajunen 2000). Accordingly, three-vessel disease was diagnosed in 
42 % of patients with and 30.3 % without diabetes (p<0.001) in the present 
study, which is similar to another recent Swedish study (Norhammar 2004). 
We identified only one previous study that compared diabetic and non-
diabetic men and women with Q-wave-MI, but this study did not analyse a 
potential interaction between sex and diabetes (Vaccarino 2000). However, 
the crude proportions did not differ between diabetic and non-diabetic 
subjects, irrespective of sex. In contrast, the diabetic women of the present 
study were significantly more likely to develop Q-wave-MI than non-
diabetic women, whereas there was no difference in men. It might be that 
the patients of the present study constitute a more representative sample, as 
all consecutive patients with suspected ACS were screened, reducing the 
risk of missing subjects with less typical presentation but who finally 
developed MI. 
Diabetes increases the risk for in-hospital mortality after MI (Malmberg 
2000, Yacccarino 2000, Gitt 2003, McGuire 2000, Cooper 1991), 
especially in women (Donahue 1993, Crowley 2003, Greenland 1991). 
However, the influence of diabetes is attenuated after adjustment for 
baseline clinical and angiographic characteristics (Cooper 1991, Granger 
1993), and some studies found a greater impact of diabetes on long-term 
than on short-term mortality (Melchior -99). In the present study, in-
hospital mortality was significantly higher in women with than without 
diabetes, irrespective of age, smoking or other diseases, whereas the 
difference between diabetic and non-diabetic men was smaller and not 
significant. Inclusion of ST-elevation or Q-wave MI in the multiple 
regression analysis did not change the results, and accordingly, the type of 
MI did not seem to influence the diabetes related mortality. However, the 
relatively low absolute number of deaths might have contributed to a type 2 
error, explaining why difference in mortality did not reach statistical 
significance in diabetic compared with non-diabetic men. 
In accordance with previous studies, (Lehto 1994, Chun 1997, Miettinen 
1998), the age-adjusted 30-day mortality was significantly increased in 
both men and women with diabetes, but slightly more so among the 
women. However, among the oldest men there was no discernible 
difference between diabetics and non-diabetics. 
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Lipid abnormalities in diabetes 
Dyslipidemia is a strong risk factor for CVD, especially in subjects with 
diabetes (Hanefeld 1996, Adlerberth 1998, Turner 1998, Sprecher 2000, 
Koivisto 2001). Serum total and LDL cholesterol levels are usually similar 
in patients with type 2 diabetes and in non-diabetics, whereas serum 
triglycerides are higher and HDL cholesterol levels are lower (UKPDS 27). 
However, elevated cholesterol levels carry similar risk of coronary artery 
disease in subjects with and without diabetes, but the absolute risk is 
considerably higher in diabetics (Stamler 1993, Adlerberth 1998). 
Furthermore, the UKPDS study clearly showed that elevated LDL and 
decreased HDL cholesterol levels were significant risk factors for coronary 
artery disease in subjects with type 2 diabetes (Turner 1998). 
In accordance with previous studies, women with prior MI in the present 
study had significantly higher triglycerides and lower HDL cholesterol 
levels than women without MI. The most adverse levels were found in 
women with both diabetes and MI. Similarly elevated TG- and decreased 
HDL levels are reported from other studies of subjects of both type 1 
(Koivisto -01) and type 2 diabetes (Uusitupa 1993, Pyörälä 1997), but few 
studies reported women separately. However, it has been claimed that the 
adverse effect of diabetes on lipid levels seems to be more marked in 
women than men (Waiden 1984). The difference in triglycerides and HDL 
cholesterol between diabetic women with and without MI of the present 
study was not explained by a poorer metabolic control, because HbAlc 
levels were similar in the two groups. 
In uncomplicated type 1 diabetic patients with good metabolic control, 
plasma lipids are in general fairly normal. However, levels of 
lipoproteinlipase (LPL), an important enzyme in LDL-cholesterol 
metabolism, decrease in insulin deficiency, and, accordingly, less well-
controlled type 1 diabetic patients may have higher levels of LDL (Reaven 
1993). Intensive insulin treatment in patients with type 1 diabetes resulted 
in significantly reduced levels of total and LDL cholesterol and of 
triglycerides, while HDL levels increased (Rosenstock 1987). 
Primary and secondary prevention of hyperlipidemia 
Several secondary prevention studies have shown the advantage of lipid 
lowering therapy in patients with CVD (4S -94, Sacks -96, Sever 2003). 
Indeed, diabetic patients at increased risk of recurrent CVD events may 
experience greater risk reduction by lipid lowering than non-diabetic 
patients (Pyörälä 1997, Goldberg 1998). 
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Recently, lipid lowering has shown to be effective also in primary 
prevention of CHD in diabetic subjects (Elkeles 1998, Collins 2003, 
Colhoun 2004), although not all studies showed significant effects (Frick 
1987, Downs 1998). As a consequence it is now recommended that all 
diabetic patients should be treated as aggressively as non-diabetic patients 
with established coronary heart disease (Expert Panel 2001, deBacker 
2003). 
Triglycerides 
The role and relative importance of elevated serum triglycerides in 
atherogenesis have been debated. As control of triglycerides and HDL 
cholesterol is interlinked through lipoprotein lipase and hepatic lipase 
activity, it may not always be feasible to separate the contributions of 
triglycerides and HDL cholesterol to coronar artery disease (Turner 1998). 
It is well known from previous studies that triglyceride levels are 
associated with previous MI when univariate analyses are performed. 
However, as in our study, the relation is often attenuated when other 
factors, especially HDL cholesterol, are adjusted for. Nevertheless, a recent 
meta-analysis reported triglycerides to be an independent risk factor for 
CVD, even after adjustment for HDL cholesterol (Austin 1998). These 
results were confirmed by several subsequent studies (Vilbergsson 1998, 
Sprecher 2000, Sharrett 2001, Iso 2001, Lindqvist 2002), although not in 
all (Turner 1998). 
The situation in women and in diabetic subjects might differ from that in 
mainly white male study populations. Several studies reported the 
association of triglyceride levels to CVD to be more pronounced in women 
than in men (Austin 1998, Vilbergsson 1998, Sprecher 2000, Iso 2001, 
Sharrett 2001). Hypertriglyceridemia is often associated with other CVD 
risk factors, and may, together with decreased HDL cholesterol, be a 
marker of a high-risk metabolic syndrome (Sprecher 2000). Furthermore, 
elevated triglycerides are a major determinant of small, dense LDL 
particles, which are considered to be highly atherogenic (Taskinen 1996). 
Haffner reported LDL size to be significantly smaller in diabetic compared 
with non-diabetic subjects of both sexes, but the association with 
hyperglycemia was stronger in women than in men (Haffner 1994). 
The cutpoints for treatment of high triglyceride levels have decreased 
during the last decades. In the 1980's, the upper desirable triglyceride level 
was <2.8 mmol/1 (NHLBI 1984). In the next decade, the level was lowered 
to <2.0 mmol/1 (Läkemedelsverket 1999, Mosca 1999). However, as the 
risk of both subsequent diabetes, as shown in the present study, and the risk 
of future MI, as reported by Miller (Miller 1998), is increased at 
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considerably lower levels, the cutpoint for desirable TG should probably 
also be lower. Indeed, the American Heart Association (Mosca 2004) and 
also Swedish health authorities (Läkemedelsverket 2003) recently lowered 
the cutpoint from 2.0 to 1.7 mmol/1, above which treatment should be 
considered. However, these new guidelines were not published when the 
present study was done. In addition, optimal triglyceride levels should 
possibly be lower in women than in men (Mosca -99). 
Smoking 
Smoking is a well established risk factor for MI in both men and women 
(Wilhelmsson 1975, Nyboe 1991, Doll 2004, Hsia 2004), and, perhaps, 
even more so in women (Nyboe 1991, Njolstad 1996, Janzon 2004). 
Besides HDL-cholesterol, smoking was the only factor that was 
independently associated with MI in women with diabetes in the present 
study. This finding confirms the previously well-known connection of 
smoking and risk of MI in diabetes (Barrett-Connor 1091, Hanefeld 1996, 
Turner 1998). It might be that smoking constitutes a stronger risk for MI in 
women than men with diabetes (Chun 1997). 
Blood pressure 
Blood pressure regulation is very important in diabetic patients, with a 
strong effect on diabetes related complications and mortality (UKPDS 38). 
Vigorous control of blood pressure decreases the risk of CVD events even 
more in patients with than without diabetes (Hansson 1998, Tuomilehto 
1999). Previous studies indicated that blood pressure reduction per se was 
important, whatever agents were used (Hansson 1998, Tuomilehto 1999). 
However, subsequent studies have indicated that inhibitors of the renin-
angiotensin system might be better, because they influence CVD morbidity 
and mortality favourably, particularly in patients with diabetes (HOPE 
2000, Lindholm 2002). Indeed, the beneficial effects of the renin-
angiotensin inhibitors on diabetic late complications might be attributable 
to mechanisms beyond the blood pressure reduction (HOPE 2000). In the 
present study, blood pressure was not a significant risk factor for MI, 
irrespective of diabetes. An explanation might be the limited number of 
participants and high utilisation of antihypertensives (Table 5). 
Oxidized LDL and inflammation 
Several lines of evidence support that modified LDL may be a key antigen 
in atherogenesis. The general hypothesis was previously that high titers of 
antibodies to modified LDL were proatherogenic (Puurunen 1994, 
Salonenl992). However, subsequent reports indicated that the immune 
response might be anti-atherogenic rather than pro-atherogenic and that 
immunisation of experimental animals with modified LDL leads to 
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dramatically enhanced IgG levels and inhibition of the progression of 
atherosclerosis (Palinski 1995, Ameli 1996, Fredriksson 2003). 
Furthermore, T-cell clones responsive to oxLDL have been isolated from 
human atherosclerotic lesions (Stemme 1995). Shaw et al demonstrated 
that naturally occurring IgM antibodies, structurally and functionally 
identical to antibodies of B-cell origin, protecting against pneumococcal 
infections, block the macrophage uptake of oxLDL in apo-E deficient mice 
(Shaw 2000). A further study showed that immunization of LDL-receptor 
deficient mice with Streptococcus pneumoniae, resulted in a marked 
increase in titers of IgM antibodies to oxLDL, and a reduction of 
atherosclerosis development (Binder 2003). Furthermore, plasma from 
these mice had the ability to block uptake of oxLDL to macrophages 
(Binder 2003). 
The lower titers of IgM among the women with diabetes and/or MI in the 
present study are in accordance with previous and subsequent studies 
where acute (Tsimikas 2003) or prior MI (Hulthe 1998) was associated 
with lower IgM titers than in controls. Furthermore, in patients with ACS, 
but not in patients with stable angina or in controls, a considerable increase 
in IgM titers following the acute event was registered (Tsimikas 2003). 
Moreover, in healthy subjects, IgM titers were inversely associated with 
carotid artery atherosclerosis (Hulthe 2001, Karvonen 2003). Thus the 
higher titer of IgM to oxLDL among the healthy women in the present 
study might reflect a protective function of the immune system. 
In contrast with titers of IgM, IgG titers were higher in women with MI 
and/or diabetes than in controls in the present study. This is in agreement 
with a previous study including both men and women, in which levels of 
IgG antibodies to MDA-LDL were significantly higher in patients with 
coronary artery diasease and/or diabetes than in controls (Griffin 1997). It 
is also in accordance with other studies, reporting elevated titers of IgG 
antibodies to MDA-LDL in men with accelerated carotid atherosclerosis 
compared to controls without progress (Salonen 1992), in men with a 
previous MI (Tornvall 2003), and in patients with angiographically verified 
multivessel coronary artery disease or ACS compared with controls (Inoue 
2001). Patients with acute MI were also demonstrated to have higher IgG 
antibody titers than controls (Inoue 2001, Tsimikas 2003). However, other 
studies showed no association between IgG titers and coronary 
atherosclerosis (McDowell 2002, van de Vijver 1996), or carotid intima­
media thickness (Uusitupa 1996, Hulthe 1998). 
Different techniques and different types of antibody preparations probably 
explain the conflicting results of the association of antibody titers to 
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oxidized LDL and atherosclerotic disease. Accordingly, during the last 
years, methods of analysing plasma levels of oxidized LDL by ELISA 
techniques based on the use of monoclonal antibodies have been 
developed. However, this technique was not available at the time of our 
study. 
Subsequent studies including both men and women have shown that 
plasma oxLDL levels are positively associated with presence of coronary 
artery disease (Holvoet 2001), and severity of ACS (Ehara 2002). Increased 
levels of circulating oxLDL were demonstrated in subjects with impaired 
glucose tolerance compaired with normal glucose tolerance (Kopprasch 
2002), and in diabetic compared with non-diabetic subjects with unstable 
angina (Ehara 2002). Furthermore, plasma levels of oxLDL were 
associated with carotid atherosclerosis (Hulthe 2002), and the metabolic 
syndrome, as well as LDL size in middle aged men (Sigurdadottir 2002). 
Kopprasch also reported a strong korrelation of oxLDL with levels of LDL 
cholesterol and triglycerides (Kopprasch 2002). Possibly, the difference in 
IgM titers between women with MI and/or DM and controls in the present 
study reflects an early, protective, immune response to the atherogenesis 
(Griffin 1997), while IgG titers may reflect atherosclerosis that is already 
manifest. 
CRP 
In recent years, the view of diabetes has widened from a disturbance in 
glucose regulation only to also include cardiovascular and inflammatory 
disburbances (Dandona 2004). Several lines of evidence suggest that 
inflammation plays an important role in atherosclerosis (Libby 2002). The 
presence of inflammation, as indicated by elevated CRP levels, predicts 
diabetes (Freeman 2002, Pradhan 2001, Hu 2004) and stroke (Rost 2001). 
Prior studies of the association of CRP to CVD were mainly limited to 
men. However, CRP is a strong, independent risk factor for CVD also in 
women, with the risk for MI or stroke being 7-fold in the highest quartile of 
CRP (Ridker -98). In accordance with this, the present study showed the 
highest CRP levels in diabetic women with MI, a group with high risk of 
recurrent CVD and death. Furthermore, the significantly higher CRP levels 
among the non-diabetic women without MI compared with controls, 
probably contributes to their increased future risk for MI (Haffner 1998), 
calling attention to the importance of careful prophylactic measures in this 
group of patients. In fact, Ridker reported CRP to be a stronger predictor of 
CVD events than LDL-cholesterol, at least in women (Ridker 2002). 
Chronic inflammation is considered to be a component of the metabolic 
syndrome (Festa 2000). Accordingly, CRP levels were elevated in 
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prediabetic subjects with insulin resistance but not in those with a primary 
defect in ß-cell function (Festa 2003). CRP was also reported to be higher 
in men with established or newly diagnosed diabetes compared with 
healthy controls (Sigurdadottir 2004). 
It is probable that the positive association of CRP with body mass index, 
waist/hip ratio, systolic blood pressure and triglycerides and negative 
association with HDL cholesterol, in confirmation of previous studies 
(Mendall 1996, Rohde 1999), do contribute to the increased CVD risk. The 
positive correlation between HbAlc and CRP in the present study, and 
reported previously by others (King 2003, Schillinger 2003), might indicate 
that a poor glycaemic control contributes to atherosclerosis not only by 
glycation but also by increased inflammation. Indeed, the Center for 
Disease Control and American Heart Association recently recommended 
assessment of CRP in patients at intermediate risk for CVD, for guidance in 
further treatment (Pearson 2003). Furthermore, in the present study CRP 
was inversely associated with IgM-antibodies to oxLDL, which 
strengthens the putative protective role of IgM antibodies. 
Multiple risk factors 
In the present study women with both diabetes and MI carried a very 
substantial risk factor burden (Paper I). Another finding was that women 
with diabetes but no prior MI had similar levels of CVD risk factors and 
inflammatory markers as the non-diabetic women who had suffered a MI 
(Paper I and II). This is in accordance with previous studies, where diabetic 
patients without prior MI had comparable risk of a primary MI as non-
diabetic subjects with prior MI to develop a reinfarktion (Haffner 1998). 
Similar results were reported for mortality after MI (Mukamal 2001) and 
unstable angina and non-Q-wave MI (Malmberg 2000, Svensson 2004). 
However, these conclusions have been challenged by others, reporting a 
history of prior MI to be a more potent predictor of cardiovascular events 
than diabetes (Simons 1998, Lotufo 2001, Evans 2002). 
A third novel observation from the present study was the association of 
even slightly elevated triglycerides with future diabetes. Furthermore, 
triglycerides are inversely correlated with HDL cholesterol (Turner 1998). 
In the prospective Tromso study (Njolstad 1998), and in the MONICA 
Augsburg cohort (Meisinger 2002) low HDL-cholesterol was a significant 
risk factor for incident diabetes. Hence, the dyslipidemia preceding 
diabetes might contribute to the increased risk of myocardial infarction 
seen in diabetic women, and explain why diabetes duration and metabolic 
control are not so strongly associated with macrovascular complications in 
diabetes type 2 (Turner 1998, Fuller -01). 
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The association between serum triglycerides and diabetes found in the 
present study was independent of obesity and high blood pressure but BMI 
> 27 kg/m2 and SBP > 145 mmHg at base-line were also independent 
predictors of diabetes. Increased triglyceride levels, obesity and 
hypertension constitute important components of the metabolic syndrome, 
which is a strong risk factor for major cardiovascular events and death in 
women (Kip 2004). This is important, reinforcing the fact that the risk of 
developing CVD in prediabetic women is increased already before the 
onset of diabetes (Hu 2002). 
In accordance with the present study, an accumulation of CVD risk factors 
among men and women with diabetes, particularly dyslipidemia, 
hypertension and obesity, is well known from previous reports (Manson 
1991, Stamler 1993, Adlerberth 1998, Hanefeld 1996, Vilbergsson 1998, 
Turner 1998, Fuller-01). Indeed, in the Multiple Risk Factor Intervention 
Trial, comprising a very large cohort of diabetic men but not including 
women, s-cholesterol, blood pressure and smoking accounted for two thirds 
of the excess deaths from CVD in diabetics (Stamler 1993) and findings in 
middle aged Göteborg men were similar (Rosengren 1989). In women with 
known CHD, the risk of reinfarction or death from coronary heart disease 
increased markedly in the presence of multiple CVD risk factors 
(Vittinghoff 2002). 
Metabolic control 
Tight metabolic control reduces the risk of microvascular complications in 
both type 1 (Holman 1983, Feldt-Rasmussen 1991, Reichard 1996, DCCT 
1993) and type 2 diabetes (UKPDS 33, Gaede 2003). Logically, an 
improved glycemic control would reduce the risk for future macrovascular 
diabetic complications as well. However, until recently an unequivocal 
effect by improved glycemic control on macrovascular complications had 
not been demonstrated (Knatternd 1978, Abraira 1997). In the Diabetes 
Control and Complications Trial (DCCT), intensive insulin treatment of 
young patients with type 1 diabetes did indeed reduce the incidence of 
cardiovascular events by 40 %. Still, the difference was not significant, 
probably due to the relatively young age of the participants and a small 
number of events during the 6.5 years mean follow-up time (DCCT 1995). 
Similarly disappointing results were reported from the United Kingdom 
Prospective Study of newly diagnosed type 2 diabetic patients. Intensive 
treatment resulted in a reduction of glycated hemoglobin by 0.9 % during 
the 10 year follow-up. However, the risk reduction for MI of 16 % was not 
significant (p=0.052), and stroke incidence was not improved at all 
(UKPDS 33). 
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In order to prevent CHD in patients with diabetes, tight glycemic control, 
although beneficial in other respects, is inadequate. Indeed, treating 
dyslipidemia and hypertension seems to be at least as important, if not 
more, in type 2 diabetes (Turner 1998). Accordingly, a recent study from 
the Steno Diabetes Center showed that intensive multiple risk factor 
intervention in patients with type 2 diabetes with microalbuminuria 
significantly reduced the risk of cardiovascular events by 50 % during 7.8 
years follow-up (Gaede 2003). Furthermore, according to Collins (Collins 
2003), several recent studies, such as the HPS study, the UKPDS and the 
HOPE studies, clearly illustrate the importance of controlling 
macrovascular risk factors beyond hyperglycemia in subjects with diabetes. 
Prevention 
One of the objectives of the present study was to explore the reasons for the 
loss of the female protection against CHD among women with diabetes. A 
conspicuous feature were the high risk factor levels among women with 
both MI and diabetes (Tables 4 and 5). Smoking and hypertension were 
more common, triglycerides higher, levels of HDL cholesterol lower, and 
plasma fibrinogen higher. In accordance with the SCORE project (Conroy 
2003), a CVD risk estimation system based on a large European pool of 
datasets from general population samples, this accumulation of risk factors 
may well explain the 2-3 times increased risk of CVD among diabetic 
women. 
Some risk factors for diabetes and CVD, such as elevated fasting glucose, 
overweight and low physical activity, are potentially reversible. Recent 
studies have shown that it is possible to reduce risk factors by life style 
intervention. Metabolic and lipid abnormalities improve with weight loss, 
exercise, smoking cessation and dietary modification. Previous studies of 
Swedish men (Eriksson 1991) and of Chinese men and women (Pan 1997) 
indicated that changes in diet and increased physical activity did prevent 
development of diabetes. These results were confirmed by the Finnish 
Diabetes Prevention Study (Tuomilehto 2001) and by the American 
Diabetes Prevention Program (Knowler 2002), showing that lifestyle 
intervention was particularly effective, as development of diabetes was 
reduced by 58 % in both men and women with impaired glucose tolerance. 
In a Swedish study of middle-aged women at risk for diabetes, one single 
counselling session on life-style changes resulted in beneficial effects in 
body mass index, blood pressure, physical activity, and dietary habits 
compared with a control group (Lidfeldt -03). Furthermore, life style 
changes in obese women without previous disease, resulted in weight loss 
and reduction in markers of inflammation and insulin resistance (Esposito 
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2003). Therefore, life style modification is the first line of therapy in 
patients at risk for, and with already developed, type 2 diabetes. 
Limitations of the study 
Study group size 
A weakness of the present study is the limited number of women with both 
DM and MI in Papers I and II. As the prevalence of MI increases with age, 
the studied groups could have been larger if the upper age limit had been 
higher. However, the rationale for selecting 64 years as the upper limit was 
the advantage of using the Mi-register and MONICA-population when 
recruiting patients and controls for the study. The MI register made it 
possible for us to identify all women who had been hospitalised for an MI 
during 1994-96, including not only those who were admitted to the 
coronary care unit (CCU). The MONICA population is well suited to serve 
as a control group, as it is a random sample of the general population. 
However, neither the MI register nor the MONICA-population comprises 
subjects older than 64 years. 
The selection process resulted in a lower mean age in control women than 
in women with DM and/or MI, as the proportion of women aged 45 to 50 
years was higher among controls than in the other groups with 
consecutively included women. To handle this, we did not match the 
patients and controls for age, but adjusted for age and other relevant factors 
in the analyses when appropriate. 
Previous studies have shown that total cholesterol and LDL-cholesterol 
levels increase when women become postmenopausal (Lindquist 1985, 
Jensen 1990. Matthews 1994, Hall 2002). However, because of the very 
strong intercorrelation between menopause and age, there was in the 
present study no independent effect of menopause. Therefore we adjusted 
for age but not menopause in the analyses. Furthermore, no studies have 
shown a rise in CVD morbidity or mortality at menopause, and 
consequently it seems that age rather than menopause influences coronary 
risk in women (Tunstall-Pedoe 1998, Barrett-Connor 1997). 
Even if the risk of MI is considerably increased in women with diabetes, 
the number of surviving women who were possible to include in Study I 
and II during the three years was limited. We have no information on 
mortality before hospital admission among women in the studied 
population. Prehospital mortality was reported to be higher in men than in 
women (Sonke 1996, Rosengren 2001, Macintyre 2001), but did not differ 
between diabetic and non-diabetic subjects with a first MI (Lehto 1994). 
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Also, Miettinen reported similar prehospital mortality in women with and 
without diabetes (Miettinen 1998). If an increased prehospital mortality 
contributed to the low number of women in the present, it would probably 
have underestimated, rather than exaggerated the differences. 
Definiton of diabetes 
In both cohorts of patients with MI/ACS of the present study (Paper I-II 
and IV), diabetes was defined by self report or by registration in medical 
records, which is a limitation. However, this is the method used in most 
studies of diabetes and CHD. With a more sensitive method for diagnosis, 
i. e. an oral glucose tolerance test (OGTT), the prevalence of diabetes 
would most probably have been higher. However, for screening purposes in 
large populations, such as in the ACS study, OGTT is difficult. For the 
case-control study (Paper I-II) an OGTT was not included. A proportion of 
patients in the present study with undiagnosed DM was therefore probably 
classified as non-diabetic. However, this potential misclassification would 
rather have attenuated than exaggerated the differences between the groups. 
Combining type 1 and type 2 diabetes 
An objection to our study could be that women with both type 1 and type 2 
diabetes were included. Age at onset and method of treatment are 
somewhat arbitrary criteria for classification of type 1 and 2 diabetes. 
However, only five women in the present study (Papers I and II), all 
without MI, were diagnosed with diabetes after age 35 and starting insulin 
treatment within one year of diagnosis. The classification of type 1 diabetes 
in these cases was subsequently confirmed by analyses of GAD-antibodies 
showing elevated levels. 
Although macro vascular disease is the major complication of type 2 
diabetes, one out of four, or 26 %, of the women with both diabetes and MI 
in Paper I and II of the present study had type 1 diabetes. This reflects the 
increased risk of MI also in type 1 diabetes, and is in accordance with 
previous studies (Borch-Jensen 1987, Rössing 1996, Laing 2003). 
Moreover, in the study by Laing et al, mortality rates in women with type 1 
diabetes were not only greater than for non-diabetic women, but were also 
considerably higher than for men without diabetes. In addition, in type 1 
diabetic patients below age 40, coronary mortality was similar in women 
and men. At ages over 40 years, mortality was higher in diabetic men than 
in women with diabetes, but the difference was smaller than among non-
diabetic subjects (Laing 2003). Similar rates of cardiovascular mortality in 
men and women with type 1 diabetes were also reported by others (Borch-
Jensen 1987, Rössing 1996, Krolewski 1997). The mean age of 56 years 
and a diabetes duration of 30 years among the type 1 women of the present 
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study is in accordance with previous studies, reporting diabetes duration 
(Koivisto 1996, Lehto 1999), and age (Krolewski 1987, Koivisto 1996, 
Rössing 1996) as risk factors for CHD in type 1 diabetes. However, in the 
Steno study, diabetes duration in type I diabetes was not related to 
cardiovascular mortality (Borch-Johnsen 1987). 
The effect of other risk factors for CHD, such as high blood pressure 
(Rössing 1996. Fuller 2001), smoking (Rössing 1996), and disturbed lipid 
levels (Koivisto 1996), seem to be similar in both types of DM. 
Accordingly, a recent study of type 1 diabetic patients showed that except 
age and albumin excretion rate, fasting triglycerides, HDL-cholesterol and 
blood pressure were signifikant predictors of CHD in women (Soedamah 
2004). Because both types of diabetes carry increased CHD risk, and as 
separating the diabetes types would have limited group sizes even more, 
the women in the study were considered together, irrespective of diabetes 
type-
Implications for the future 
The present data indicate that the atherosclerotic process, with a 
concomitant inflammatory response, might already be well under way in 
women with diabetes even in the absence of clinical signs of 
atherosclerosis. Furthermore, increased levels of CVD risk factors in the 
pre-diabetic phase might be of great importance for the subsequent risk of 
MI in subjects who later develop diabetes. Therefore, elevated triglycerides 
should be concerned at least in women. The accumulation of modifiable 
CVD risk factors in women with diabetes, and in women at risk of diabetes, 
indicate the importance of implementing well-known non-pharmacological 
and pharmacological measures directed towards metabolic control, weight 
reduction, increased physical activity, smoking cessation, and effective 
treatment of hyperlipidemia and hypertension to attenuate the risk for 
future cardiovascular disease. Both primary and secondary preventive 
measures are therefore of considerable importance to decrease morbidity 
and mortality among women with diabetes. Furthermore, as symptom 
presentation, clinical course and prognosis differ between the sexes, it is 
important to analyse men and women separately in studies on diabetes and 
ACS. 
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CONCLUSIONS 
Women with diabetes who have manifested a MI carry a very 
substantial cardiovascular risk factor burden. 
The findings also indicate a pronounced inflammation and 
differentiated immune response against modified LDL that might result 
in a more aggressive atherosclerotic process in women with diabetes 
and/or MI. 
Women with diabetes but no MI have a similar risk factor profile as 
non-diabetic women with manifest coronary disease. 
Among previously healthy middle-aged Swedish women even slightly 
elevated triglyceride levels and moderately increased blood pressure 
and body mass index have a strong influence on diabetes risk 
independent of other factors. 
The accumulation of unfavourable risk factors in women long before 
diabetes has developed, might contribute to the increased risk of 
cardiovascular disease found in women with diabetes. 
In patients admitted to hospital with ACS, women with diabetes more 
often present with ST-elevation, are more likely to develop Q-wave MI, 
and have a worse prognosis than non-diabetic women, whereas the 
difference between men with and without diabetes is less pronounced. 
These findings suggest a different effect of diabetes on the 
pathophysiology of ACS based on the patient's sex. 
The results of the present study emphasize the importance of analysing 
men and women separately in studies on ACS and diabetes. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Bakgrund: Diabetes mellitus är en metabol sjukdom som orsakar förhöjt 
blodsocker beroende på för liten insulinproduktion, nedsatt 
insulinkänslighet eller en kombination av båda dessa faktorer. Förekomsten 
av framför allt typ 2 diabetes, som ofta har samband med övervikt, låg 
fysisk aktivitet, förhöjda blodfetter och högt blodtryck, ökar kraftigt. 
Beräkningar visar att diabetesfrekvensen kommer att fördubblas till år 
2030, då man förväntar att ca 350 miljoner människor i världen kommer att 
vara drabbade. 
Kardiovaskulär sjukdom, dvs hjärtinfarkt, stroke och andra 
åderförkalkningssjukdomar, är den största enskilda orsaken till sjuklighet 
och död hos diabetiker. Medan förekomsten av diabetes i befolkningen är 
3-6%, finner man att 20-25% av patienter med hjärtinfarkt har känd 
diabetes, en nästan lika stor andel har tidigare odiagnosticerad diabetes och 
ytterligare en andel har nedsatt glukostolerans, ett förstadium till diabetes. 
Studier har visat att bara ca 1/3 av patienter med hjärtinfarkt har normal 
glukosomsättning. 
Diabetiker löper således en avsevärt ökad risk för hjärtinfarkt och 
kardiovaskulär död jämfört med icke-diabetiker. Vidare tycks kvinnor med 
diabetes vara särskilt drabbade. I Västvärlden har dödligheten i 
kranskärlssjukdom minskat de senaste årtiondena. Emellertid har 
dödligheten minskat i mindre grad bland män med diabetes, medan den inte 
har minskat, eller, enligt vissa forskare, till och med har ökat, bland kvinnor 
med diabetes. 
Det är välkänt att rökning, högt blodtryck, övervikt och blodfettrubbning 
har stor betydelse för utvecklingen av ateroskleros, en process där även 
immunsystemet och inflammatorisk aktivitet tycks spela en viktig roll. 
Diabetiker har en mer uttalad ateroskleros än icke-diabetiker och 
karaktäriseras ofta av ett ogynnsamt kardiovaskulärt riskfaktormönster. 
Oftast finner man ingen skillnad mellan diabetiker och icke-diabetiker vad 
gäller nivåer av total- och LDL kolesterol, medan förhöjda triglycerider och 
sänkt HDL-kolesterol är vanligare hos diabetiker. Förhöjt LDL kolesterol 
medför visserligen samma ökade risk för hjärtinfarkt hos diabetiker och 
ickediabetiker, men den absoluta risken är avsevärt högre hos diabetiker. 
Emellertid finns det inte så många studier där man undersökt hur dessa 
faktorer bidrar till risken för hjärtinfarkt hos kvinnor med diabetes. 
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Vid akut koronarsyndrom (ACS), dvs hjärtinfarkt och instabil kärlkramp, 
tycks diabetiker uppvisa annorlunda symtom, sjukdomsförlopp och prognos 
än icke-diabetiker, men den kliniska bilden hos speciellt kvinnor med 
diabetes är inte så väl belyst. 
Syfte: Syftet med projektet är att belysa frågan om varför diabeteskvinnor 
förlorar skyddet mot hjärtinfarkt. Vi undersökte därför kardiovaskulära 
riskfaktorer som karaktäriserar kvinnor med diabetes och genomgången 
hjärtinfarkt i jämförelse med infarktkvinnor utan diabetes, diabeteskvinnor 
utan infarkt och friska kontroller. Vi studerade också sambandet mellan 
immunsvaret, speglat av antikroppstitrar mot oxiderat LDL-kolesterol, 
CRP, som markör för inflammation, diabetes och hjärtinfarkt hos kvinnor. 
Vidare undersökte vi faktorer av betydelse för risken att utveckla diabetes 
och effekten av diabetes på kliniska symtom, sjukdomsförlopp och prognos 
hos kvinnor och män med ACS. 
Metodik: Kvinnor med (n=29) och utan (n=64) diabetes som haft 
hjärtinfarkt 1994-96 jämfördes med diabeteskvinnor som inte haft 
hjärtinfarkt (n=46) och friska kontroller (n=125). Riskfaktorer för hjärt-
kärlsjukdom registrerades med hjälp av frågeformulär, mätningar av 
kroppsmått och blodtryck och blodanalyser (studie I). Vidare bestämdes 
antikroppar mot oxiderat LDL-kolesterol och CRP som mått på immunsvar 
och inflammatorisk aktivitet (studie II). 
1979-81 undersöktes 1351 ur befolkningen slumpvist utvalda, tidigare 
friska kvinnor, 39-65 år gamla, med frågeformulär, kroppsundersökning 
och blodanalyser. Utveckling av diabetes i denna grupp studerades vid en 
uppföljning 1997-98 (studie III). 
Vidare undersöktes inom ramen för Euro Heart Survey ACS 6488 män 
(21,2% diabetes) och 2809 kvinnor (28,7% diabetes) som vårdats på 
europeiska sjukhus med diagnos ACS. Symtom, vårdförlopp och prognos 
bedömdes med hjälp av registerdata (studie IV). 
Resultat: Diabeteskvinnor med hjärtinfarkt hade kraftigt förhöjda nivåer av 
konventionella riskfaktorer. De var i högre utsträckning rökare och mer 
fysiskt inaktiva än de övriga kvinnorna, hade signifikant högre midj e/stuss 
omfång och s-triglycerider, och signifikant lägre HDL-kolesterol än 
diabeteskvinnor utan hjärtinfarkt. Infarktkvinnor utan diabetes hade 
intermediära värden för dessa parametrar. Såväl kvinnor med diabetes som 
de med hjärtinfarkt hade ett rubbat immunsvar med signifikant högre titrar 
av IgG och lägre titrar av IgM antikroppar mot oxiderat LDL. Vidare hade 
de högre CRP nivåer än de friska kontrollkvinnorna. 
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Förhöjda triglycerider, övervikt, högt blodtryck och låg fysisk aktivitet 
ökade risken för senare utveckling av diabetes. Även lätt förhöjda 
triglycerider, dvs nivåer som normalt inte anses indikera ökad risk för 
kardiovaskulär sjukdom, medförde avsevärt ökad risk för diabetes 
oberoende av övriga faktorer. 
Vid ACS påverkade diabetes sjukdomsbilden på olika sätt hos män och 
kvinnor. Kvinnor med diabetes utvecklade signifikant oftare ST-höjning på 
EKG, Q-vågs infarkt och hade också ökad sjukhusmortalitet jämfört med 
kvinnor utan diabetes. Män med diabetes hade större benägenhet att 
utveckla instabil kärlkramp och icke-Q-vågs infarkt jämfört med män utan 
diabetes, men skillnaden var inte signifikant vid justering för 
bakgrundsfaktorer. 
Slutsats: Diabeteskvinnor med genomgången hjärtinfarkt har avsevärt 
förhöjda nivåer av kardiovaskulära riskfaktorer. Fynden indikerar också en 
förändrad immunrespons mot modifierat LDL-kolesterol och en mer uttalad 
inflammation hos kvinnor med diabetes och/eller hjärtinfarkt jämfört med 
friska kvinnor. 
Diabeteskvinnor utan hjärtinfarkt har en riskfaktorprofil som mer liknar 
infarktkvinnorna än de friska kvinnorna. 
Bland tidigare friska medelålders kvinnor innebär även lätt förhöjda 
triglycerider en betydligt ökad risk för diabetes under 18 års uppföljning, 
oberoende av ålder, vikt, blodtryck och fysisk aktivitet. 
Förekomst av rubbade riskfaktomivåer redan innan diabetes diagnostiseras 
skulle kunna bidra till den ökade hjärtinfarktrisken hos kvinnor med 
diabetes. 
Vid ACS medför diabetes en högre sannolikhet för ST-höjning på EKG, 
utveckling av Q-vågs infarkt och sämre prognos hos kvinnor, medan 
skillnaderna mellan män med och utan diabetes är mindre uttalade. Detta 
skulle kunna tala för att diabetes har olika effekt på patofysiologin vid 
koronarsjukdom hos kvinnor och män. 
I studier av diabetes och hjärtsjukdom bör kvinnor och män analyseras var 
för sig. 
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